RecruitingNot ApplicableNCT04754672

Aerobic Fitness or Muscle Mass Training to Improve Colorectal Cancer Outcome

Aerobic Fitness or Muscle Mass Training to Improve Colorectal Cancer Outcome (AMICO). The Effects of Exercise on Chemotherapy Dose Modification and Progression Free Survival in Patients With Metastatic Colorectal Cancer


Sponsor

Radboud University Medical Center

Enrollment

228 participants

Start Date

Mar 2, 2021

Study Type

INTERVENTIONAL

Conditions

Summary

Evidence from randomized controlled trials shows that exercise during cancer treatment benefits physical fitness, fatigue and quality of life. Since the effect of exercise on clinical outcome is currently unknown, exercise is not included as integral part of standard cancer care. Moreover, evidence regarding the optimal exercise prescription in terms of type and dose is lacking. To maintain quality of life in patients receiving palliative treatment with chemotherapy, toxicity-induced modifications in the prescribed chemotherapy dose are common. Such modifications - occurring in 40% of patients with metastatic colorectal cancer - may reduce benefit of treatment. The investigators hypothesize that exercise prevents chemotherapy dose modifications by reducing toxicity and enhancing psychological strength. Additionally, based on studies in rodents and preliminary data in patients with cancer, the researchers hypothesize that exercise has beneficial effects on the functionality of the natural killer cells, which play an important role in the innate immune defense against cancer. Both, fewer dose modifications and improved immune function may improve progression-free survival. This study is a three-armed trial comparing resistance exercise, aerobic interval exercise and usual care in patients with metastatic colorectal cancer to select the optimal exercise prescription for preventing chemotherapy dose modifications. The trial will use a Bayesian adaptive multi-arm multi-stage design with several interim analyses after which an ineffective study arm can be dropped early. This novel design makes the trial more efficient and reduces patients' exposure to suboptimal study arms. Evidence regarding the exercise effects on i) clinical outcome, ii) the optimal exercise prescription, and iii) the underlying mechanisms, elucidates the potential of exercise to boost benefit from chemotherapy treatment. This evidence provides leads to improve progression-free survival and quality of life of patients suffering from one of the leading causes of cancer death worldwide.


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study compares two types of exercise training programs — one focused on aerobic fitness and one on building muscle — to see which better helps people with advanced colorectal cancer tolerate chemotherapy and improve their outcomes. **You may be eligible if...** - You have metastatic colorectal cancer (cancer that has spread) and are starting palliative chemotherapy - You are scheduled for first-line doublet or triplet chemotherapy - You are able and willing to give consent and participate in exercise training **You may NOT be eligible if...** - Your life expectancy is less than 6 months - You are unable to walk or bike or perform basic physical activities - You have cognitive problems that would prevent participation Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BEHAVIORALContinuous aerobic and resistance exercise intervention

Continuous aerobic and resistance exercises intervention

BEHAVIORALContinuous aerobic and aerobic interval exercise intervention

Continuous aerobic and aerobic interval exercise intervention


Locations(13)

Jeroen Bosch Ziekenhuis

's-Hertogenbosch, Netherlands

Flevoziekenhuis

Almere Stad, Netherlands

Meander Medisch Centrum

Amersfoort, Netherlands

Ziekenhuis Amstelland

Amstelveen, Netherlands

Amsterdam UMC

Amsterdam, Netherlands

Netherlands Cancer Institute

Amsterdam, Netherlands

Rijnstate Ziekenhuis

Arnhem, Netherlands

Ziekenhuis Amphia

Breda, Netherlands

Catharina Ziekenhuis

Eindhoven, Netherlands

Spaarne Gasthuis

Hoofddorp, Netherlands

Radboudumc

Nijmegen, Netherlands

Canisius Wilhelmina Ziekenhuis

Nijmegen, Netherlands

UMCU

Utrecht, Netherlands

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04754672


Related Trials